Vir Biotechnology, Inc. (VIR) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Vir Biotechnology, Inc. (VIR) Healthcare & Pipeline Overview

Vir Biotechnology, Inc. is a commercial-stage immunology company specializing in developing antibody-based therapies for infectious diseases such as COVID-19, hepatitis B, influenza A, and HIV. The company leverages collaborations and licensing agreements to advance its pipeline and address unmet medical needs in the infectious disease space.

What Is the Investment Thesis for VIR?

The company's Sotrovimab demonstrated efficacy against COVID-19, generating significant revenue. Future growth is expected to be driven by the advancement of its HBV and influenza programs, particularly VIR-2218 and VIR-2482. Key value drivers include successful clinical trial outcomes, regulatory approvals, and strategic partnerships. The company's gross margin stands at 275.2%. However, the company's negative profit margin of -676.0% indicates that it is not yet profitable. The company's beta of 1.66 suggests that the stock is more volatile than the market. Investors should monitor clinical trial data, regulatory decisions, and partnership developments to assess the company's long-term potential.

Based on FMP financials and quantitative analysis

VIR Key Highlights

Vir Biotechnology has a market capitalization of $1.78B, reflecting investor valuation of its pipeline and technology.

• The company's gross margin is 275.2%, indicating strong pricing power on its commercialized products.
• Vir Biotechnology has a negative profit margin of -676.0%, reflecting substantial R&D investments and operating expenses.
• The company's beta is 1.66, indicating higher volatility compared to the broader market.
• Vir Biotechnology collaborates with leading pharmaceutical companies like GlaxoSmithKline and Gilead Sciences, validating its scientific approach.

Who Are VIR's Competitors?

VIR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are VIR's Key Strengths?

Innovative antibody platform for infectious disease therapies.

• Strong pipeline of therapeutic candidates targeting unmet medical needs.
• Strategic collaborations with leading pharmaceutical companies.
• Experienced management team with expertise in immunology and drug development.

What Are VIR's Weaknesses?

Reliance on partnerships for funding and development.

• Dependence on regulatory approvals for commercial success.
• Competition from established pharmaceutical companies.
• Negative profit margin.

What Could Drive VIR Stock Higher?

Clinical trial results for VIR-2218 in hepatitis B virus (HBV) patients.

• Clinical trial results for VIR-2482 in influenza A prevention.
• Potential new partnerships or collaborations to expand the pipeline.
• Regulatory updates regarding the approval of VIR-2218 or VIR-2482.

What Are the Key Risks for VIR?

Negative return on equity (-30.0%) — the business is not currently generating profit on shareholder capital.

• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for key pipeline candidates.
• Regulatory setbacks or delays in approval processes.
• Competition from established pharmaceutical companies and biosimilars.
• Dependence on partnerships for funding and development.
• Intellectual property challenges or patent disputes.

What Are the Growth Opportunities for VIR?

• Growth opportunity 1: Development of VIR-2218 for Hepatitis B Virus (HBV): VIR-2218 is an RNAi therapeutic designed to suppress HBV replication. The global market for HBV treatments is expected to reach $4.2 billion by 2028. Successful clinical trials and regulatory approval could drive significant revenue growth for Vir Biotechnology. The company is also developing VIR-3434, another HBV treatment, which could further expand its market share.
• Growth opportunity 2: Advancement of VIR-2482 for Influenza A: VIR-2482 is a broadly neutralizing antibody targeting influenza A. The influenza vaccine market is estimated at $6.8 billion. VIR-2482 has the potential to provide superior protection compared to existing vaccines, driving adoption and market share gains. Clinical trials are ongoing to evaluate its efficacy and safety.
• Growth opportunity 3: Expansion of Sotrovimab (Xevudy) for COVID-19: While the COVID-19 pandemic has subsided, the need for effective treatments remains, particularly for vulnerable populations. Sotrovimab, marketed as Xevudy, is a SARS-CoV-2-neutralizing monoclonal antibody. Continued sales of Sotrovimab could provide a steady revenue stream for Vir Biotechnology. The company is also exploring next-generation COVID-19 therapies.
• Growth opportunity 4: Strategic Partnerships and Collaborations: Vir Biotechnology has established collaborations with leading pharmaceutical companies and research institutions. These partnerships provide access to innovative technologies, funding, and expertise. Continued strategic collaborations could accelerate drug development and expand the company's pipeline. The company's collaboration with Gilead Sciences for chronic hepatitis B virus is particularly promising.
• Growth opportunity 5: Development of VIR-1111 for HIV Prevention: VIR-1111 is an HIV prevention therapy. The global market for HIV prevention is substantial. Successful development and commercialization of VIR-1111 could generate significant revenue for Vir Biotechnology. The company is conducting preclinical and clinical studies to evaluate its safety and efficacy.

What Opportunities Does VIR Have?

• Expansion of its pipeline through internal research and development.
• Acquisition of complementary technologies and assets.
• Geographic expansion into emerging markets.
• Development of new therapies for emerging infectious diseases.

What Are VIR's Competitive Advantages?

• Proprietary antibody platform for developing infectious disease therapies.
• Strong intellectual property portfolio protecting its therapeutic candidates.
• Strategic collaborations with leading pharmaceutical companies and research institutions.
• Expertise in immunology and infectious disease research.

What Does VIR Do?

Vir Biotechnology, Inc., founded in 2016 and headquartered in San Francisco, California, is dedicated to combating serious infectious diseases. The company's mission is to combine immunologic insights with cutting-edge technologies to create effective therapeutic and preventative solutions. Vir's pipeline includes programs targeting diseases such as COVID-19, hepatitis B virus (HBV), influenza A virus, and human immunodeficiency virus (HIV). Its lead product, Sotrovimab (marketed as Xevudy), is a SARS-CoV-2-neutralizing monoclonal antibody developed for the treatment and prevention of COVID-19. Other key programs include VIR-2218 and VIR-3434 for HBV, VIR-2482 for influenza A, and VIR-1111 for HIV. Vir Biotechnology strategically collaborates with organizations like the Bill & Melinda Gates Foundation, the National Institutes of Health, Alnylam Pharmaceuticals, Brii Biosciences, WuXi Biologics, GlaxoSmithKline, and Gilead Sciences to accelerate its research and development efforts. These collaborations encompass licensing agreements, research collaborations, and manufacturing agreements, enabling Vir to leverage external expertise and resources to advance its therapeutic candidates through clinical development and commercialization.

What Products and Services Does VIR Offer?

• Develops antibody-based therapies for infectious diseases.
• Focuses on treatments and preventatives for COVID-19.
• Creates therapies for hepatitis B virus (HBV).
• Develops solutions for influenza A virus.
• Works on HIV prevention therapies.
• Collaborates with pharmaceutical companies and research institutions.
• Conducts clinical trials to evaluate the safety and efficacy of its therapies.

How Does VIR Make Money?

• Develops and commercializes therapeutic products for infectious diseases.
• Generates revenue through sales of its commercialized products, such as Sotrovimab.
• Partners with pharmaceutical companies to co-develop and commercialize its therapies.
• Receives grant funding from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health.

What Industry Does VIR Operate In?

Vir Biotechnology operates within the biotechnology industry, which is characterized by high growth potential and significant R&D investments. The market for infectious disease therapeutics is driven by the emergence of new pathogens, increasing antibiotic resistance, and the need for preventative vaccines and treatments. The competitive landscape includes established pharmaceutical companies and specialized biotech firms focused on specific disease areas. Vir Biotechnology differentiates itself through its focus on immunology and its diversified pipeline of antibody-based therapies. The company's collaborations with leading research institutions and pharmaceutical companies provide a competitive advantage in accessing innovative technologies and accelerating drug development.

Who Are VIR's Key Customers?

• Patients suffering from infectious diseases such as COVID-19, hepatitis B, influenza A, and HIV.
• Healthcare providers who prescribe and administer Vir Biotechnology's therapies.
• Government agencies and public health organizations that purchase and distribute Vir Biotechnology's products.
• Pharmaceutical companies that partner with Vir Biotechnology to co-develop and commercialize its therapies.

Vir Biotechnology, Inc. (VIR) Valuation Context

Valued at $1.78B, VIR is classified as a small-cap stock. Analyst price targets span from $25.00 to $25.00, with a consensus of $25.00. At the current price of $10.58, that implies approximately 136% upside potential. Relative to its peer group, VIR's quantitative score of 27/100 is below the peer average of 81/100.

VIR Revenue & Earnings Trend

In Q2 FY2026, VIR generated $238.9M in top-line revenue. The company recorded net income of $80.1M, with diluted EPS of $0.47. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, VIR averaged $-0.47 in diluted EPS.

Company Profile

Vir Biotechnology, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Francisco, US. The company is led by CEO Marianne De Backer. VIR has traded publicly since 2019.

Return on equity for Vir Biotechnology, Inc. stands at -30.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -20.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -17.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.04 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -13.1%, the inverse of the P/E and a quick read on earnings relative to price.

Vir Biotechnology, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 3.20 places it in the safe zone, indicating low near-term bankruptcy risk.

Vir Biotechnology, Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 1058.6% below estimates on average.

Over the past six months, Vir Biotechnology, Inc. insiders filed 27 SEC Form 4 transactions — 9 sales and 18 purchases. On net that is roughly 48K shares acquired (about $179K) — insiders putting money in tends to read as conviction.

VIR Financials

VIR Latest News

VIR Analyst Consensus

VIR MoonshotScore

Vir Biotechnology, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources